April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Improvements in Reading Speed After 6 Months of Ranibizumab Treatment in Bravo and Cruise
Author Affiliations & Notes
  • I. J. Suner
    Retina Associates of Florida, Tampa, Florida
  • R. Varma
    Ophthalmology, USC, Doheny Eye Institute, Los Angeles, California
  • N. M. Bressler
    Ophthalmology, Wilmer Eye Institute, Baltimore, Maryland
  • P. P. Lee
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • C. Dolan
    Genentech, South San Francisco, California
  • J. Ward
    Genentech, South San Francisco, California
  • S. Colman
    Genentech, South San Francisco, California
  • R. Rubio
    Genentech, South San Francisco, California
  • Footnotes
    Commercial Relationships  I.J. Suner, Genentech, F; Genentech, Pfizer, Eyetech, Comentis, C; R. Varma, Allergan, Aqueys, Genentech, Optovue, Pfizer, F; Allergan, Aqueys, Bausch & Lomb, Genentech, Laboratorios Sophia, Pfizer, C; N.M. Bressler, Genentech, F; P.P. Lee, Genentech, Merck, F; Alcon, Allergan, Genentech, Merck, Pfizer, C; Alcon, Allergan, Genentech, Merck, Pfizer, R; C. Dolan, Genentech, C; J. Ward, Genentech, C; S. Colman, Genentech, E; R. Rubio, Genentech, E.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 945. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      I. J. Suner, R. Varma, N. M. Bressler, P. P. Lee, C. Dolan, J. Ward, S. Colman, R. Rubio; Improvements in Reading Speed After 6 Months of Ranibizumab Treatment in Bravo and Cruise. Invest. Ophthalmol. Vis. Sci. 2010;51(13):945.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To examine the efficacy of ranibizumab (Lucentis®) on measured reading speed using a reading speed test through 6 months in subjects with macular edema following retinal vein occlusion (RVO).


Two multicenter, double-masked, phase III trials in which participants with macular edema following branch RVO (BRAVO) or central RVO (CRUISE) were randomized 1:1:1 to monthly sham, 0.3-mg or 0.5-mg ranibizumab for 6 months. Reading speed in the study eye was measured using a test designed by the Macular Photocoagulation Study group through collaboration with the Lighthouse in New York. The number of correctly read words per minute is reported. The test requires a maximum 6th grade reading level. It does not take into account literacy or cognitive state. The reading speed test was administered at 0, 1, 3, and 6 months.


At 6 months, ranibizumab-treated patients had greater mean gains in reading speed in study eyes than patients with sham-treated study eyes (Figure).


In BRAVO and CRUISE, patients with macular edema following RVO subsequently treated monthly with ranibizumab had, on average, greater improvements in reading speed in study eyes, a direct patient performance assessment of reading ability and visual function, through 6 months compared with sham treatment.  

Clinical Trial:

www.clinicaltrials.gov NCT00486018, NCT00485836

Keywords: quality of life • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • macula/fovea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.